Where nasal drug development goes wrong, and how to get ahead of it
Bespak and Upperton's collaboration helps developers align nasal drug formulation, device and manufacturing decisions early to reduce rework and risks.
Dry Powder Inhaler Devices Supporting High-Precision Drug Delivery
Manufacturers utilize the dry powder inhaler to support high precision drug delivery for biologics and small molecules requiring stable aerosolization.
Nasal Unit-Dose Devices Improving Intranasal Drug Delivery Control
Unit dose devices improve intranasal drug delivery control by providing precise dosing for systemic and local treatments in diverse patient populations.
Soft Mist Inhaler Platforms Improving Low-Velocity Drug Delivery
Soft mist inhaler platforms optimize low-velocity drug delivery by producing fine aerosols that penetrate deep into the lungs with minimal patient effort.
Triple-Combination pMDIs Expanding Complex Inhalation Drug Delivery
Triple combination therapies expand inhalation drug delivery options for chronic respiratory diseases by integrating multiple active pharmaceutical ingredients.
Integrated counters enhance pMDI dose tracking by providing accurate usage data for patients and clinicians to improve respiratory therapy adherence rates.
